Assessing the effect of selective serotonin reuptake inhibitors in the prevention of post-acute sequelae of COVID-19.

ABSTRACT:

Background

Post-acute sequelae of COVID-19 (PASC) produce significant morbidity, prompting evaluation of interventions that might lower risk. Selective serotonin reuptake inhibitors (SSRIs) potentially could modulate risk of PASC via their central, hypothesized immunomodulatory, and/or antiplatelet properties although clinical trial data are lacking.

Materials and methods

This retrospective study was conducted leveraging real-world clinical data within the National COVID Cohort Collaborative (N3C) to evaluate whether SSRIs with agonist activity at the sigma-1 receptor (S1R) lower the risk of PASC, since agonism at this receptor may serve as a mechanism by which SSRIs attenuate an inflammatory response. Additionally, determine whether the potential benefit could be traced to

SUBMITTER: Sidky H 

PROVIDER: S-EPMC10839808 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature